168 related articles for article (PubMed ID: 29237024)
1. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline.
Turner RB; Wilson DE; Saedi-Kwon H; Chang E; Won R; Chan D; Schwartz J
J Antimicrob Chemother; 2018 Mar; 73(3):772-778. PubMed ID: 29237024
[TBL] [Abstract][Full Text] [Related]
2. Neutropenia Associated with Long-Term Ceftaroline Use.
LaVie KW; Anderson SW; O'Neal HR; Rice TW; Saavedra TC; O'Neal CS
Antimicrob Agents Chemother; 2016 Jan; 60(1):264-9. PubMed ID: 26503657
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Neutropenia Associated with Ceftaroline or Ceftriaxone in Patients Receiving at Least 7 Days of Therapy for Severe Infections.
Veve MP; Stuart M; Davis SL
Pharmacotherapy; 2019 Aug; 39(8):809-815. PubMed ID: 31257604
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
5. A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline.
Yam FK; Kwan BK
Am J Health Syst Pharm; 2014 Sep; 71(17):1457-61. PubMed ID: 25147169
[TBL] [Abstract][Full Text] [Related]
6. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Zasowski EJ; Trinh TD; Claeys KC; Casapao AM; Sabagha N; Lagnf AM; Klinker KP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895012
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia.
Kufel WD; Parsels KA; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ
Pharmacotherapy; 2023 Jan; 43(1):15-23. PubMed ID: 36371648
[TBL] [Abstract][Full Text] [Related]
8. High incidence of neutropenia in patients with prolonged ceftaroline exposure.
Furtek KJ; Kubiak DW; Barra M; Varughese CA; Ashbaugh CD; Koo S
J Antimicrob Chemother; 2016 Jul; 71(7):2010-3. PubMed ID: 27076105
[TBL] [Abstract][Full Text] [Related]
9. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
10. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
11. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline - a cause for neutropenia.
Rimawi RH; Frenkel A; Cook PP
J Clin Pharm Ther; 2013 Aug; 38(4):330-2. PubMed ID: 23590618
[TBL] [Abstract][Full Text] [Related]
14. Rate and Incidence of Adverse Reactions Associated With Ceftaroline Exposure: Importance of Cutaneous Manifestations.
Jansen JW; Moenster RP
Ann Pharmacother; 2018 Mar; 52(3):235-239. PubMed ID: 28980484
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia.
Burnett YJ; Echevarria K; Traugott KA
Ann Pharmacother; 2016 Dec; 50(12):1051-1059. PubMed ID: 27520326
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.
Nigo M; Diaz L; Carvajal LP; Tran TT; Rios R; Panesso D; Garavito JD; Miller WR; Wanger A; Weinstock G; Munita JM; Arias CA; Chambers HF
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28232309
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy.
Sakoulas G
Clin Adv Hematol Oncol; 2008 Nov; 6(11):813-5. PubMed ID: 19194364
[No Abstract] [Full Text] [Related]
19. Review: Daptomycin for the treatment of gram-positive infections in neutropenic cancer patients.
Rolston KV
Clin Adv Hematol Oncol; 2008 Nov; 6(11):815-7. PubMed ID: 19194365
[No Abstract] [Full Text] [Related]
20. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
Barber KE; Rybak MJ; Sakoulas G
J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
